Non-Hodgkins lymphoma of bilateral eyelids with basal cell carcinoma of nose: a rare case report

Malignant tumours affecting the eyelid mainly include basal cell carcinoma. Non-Hodgkin抯 lymphoma may occur in almost any part of the body and should be considered in the differential diagnosis of extra lymphoid tumours. Non- Hodgkin抯 lymphoma of the eyelid is rare. Rare diseases should be considered in differential diagnoses because they have the tendency for rapid systemic involvement and they may require treatments that are different from the other common diseases. Basal cell carcinoma occurs most frequently at sun-exposed sites, most commonly in the head and neck regions. The aim of any therapy selected for BCC treatment involving the head and neck is to ensure complete removal, functional preservation, and a good cosmetic outcome. Here, we reported a case of a 70-year-old female with non-Hodgkin lymphoma of eyelids followed by basal cell carcinoma of the nose treated with multimodality approach.

Recurring basal cell carcinoma involvingexclusively intra-oral mucosa: a case report

Basal cell carcinoma (BCC) is the most common skin cancer, but oral involvement is extremely rare. Here, we showed a case of a 71-year-old Caucasian male patient presenting an asymptomatic submucosal nodule in the left buccal mucosa on the same side of a previous BCC skin lesion. Intraoral examination revealed a circumscribed sessile and fibrous mass covered by normal mucosa. An incisional biopsy was performed. Microscopically, the lesion showed uniform, ovoid, dark-staining basaloid cells with medium-sized nuclei and little cytoplasm arranged in islands and strands, invading the underlying connective tissue. These islands demonstrated palisading of the peripheral cells and occasionally central areas with epidermoid differentiation. The final diagnosis was nodular basal cell carcinoma. Although uncommon, recurrent BCC may occur in the oral cavity. (AU)

Management of facial bacal cell carcinoma in rural hospital: a case report

Basal cell carcinoma is usually a slow-growing tumor for which metastases are rare. Basal Cell Carcinoma is the most common type of skin cancer around 75-80%. We present the case of A 87-year-old woman presented with a chief complaint of a reddish-brown nodule on the right side of her face. The complaint has been about 4 months, initially small in size as a mole but grew progressively to its current size. It is known that his daily work is as a farmer. However, one of the main problems of BCC is the cosmetic appearance, especially in the facial area.

Carcinoma basocelular de vulva: relato de caso / Basal cell carcinoma of the vulva: case report

Introdução: O carcinoma basocelular (CBC) de vulva é uma condição rara que corresponde a menos de 0,4% dos casos de CBC e de 2% a 4% das neoplasias de vulva. O CBC de vulva é mais comum entre mulheres brancas, multíparas e na pósmenopausa, especialmente na sétima década de vida. O objetivo é relatar um caso de CBC de vulva no qual discutiram-se os aspectos do diagnóstico e tratamento. Relato de Caso: Mulher de 63 anos de idade, G1P1A0, chega ao consultório em janeiro de 2022 para tratamento de lesão persistente em vulva. Realizou-se biópsia incisional que mostrou tratar-se de provável carcinoma basocelular nodular com invasão da derme. A paciente submeteu-se a uma ressecção do tumor com margens macroscópicas livres e sutura primária. A cirurgia não teve complicações no pré-operatório e no pós-operatório. O histopatológico da peça cirúrgica mostrou tratar-se de carcinoma basocelular nodular com área irregular, plana, branco, medindo 0,7x0,4cm, com as margens laterais distando 7,0 e 5,0mm e profundas, 5,9mm; todas livres. Conclusão: O caso relatado é raro, tendo sido o tratamento de ressecção cirúrgica do CBC de vulva com margens bem-sucedido. Catorze meses após a cirurgia, a paciente encontra-se sem evidências de recidiva local ou regional.

Introduction: Basal cell carcinoma (BCC) of the vulva is a rare condition that accounts for less than 0.4% of BCC cases and 2% to 4% of vulvar neoplasms. BCC of the vulva is more common among white, multiparous and postmenopausal women, especially in the seventh decade of life. The aim is to report a case of BCC of the vulva in which aspects of diagnosis and treatment were discussed. Case report: A 63-year-old woman, G1P1A0, arrives at the office in January 2022 for treatment of a persistent lesion on her vulva. An incisional biopsy was performed and showed that it was likely nodular basal cell carcinoma with invasion of the dermis. The patient underwent tumor resection with free macroscopic margins and primary suture. The surgery had no complications preoperatively or postoperatively. The histopathology of the surgical specimen showed that it was a nodular basal cell carcinoma with an irregular, flat, white area, measuring 0.7x0.4cm, with the lateral margins 7.0 and 5.0mm apart and 5.9mm deep; all free. Conclusion: The reported case is rare, with surgical resection of BCC of the vulva with margins being successful. Fourteen months after surgery, the patient has no evidence of local or regional recurrence.

Tumor filoide borderline gigante e recidivante: ressecção e reconstrução da mama / Recurrent giant borderline phyllodes tumor: resection and breast reconstruction

O tumor filoide é uma neoplasia fibroepitelial rara que representa 0,3 a 1% de todas as neoplasias mamárias. De acordo com a classificação histopatológica, 12 a 26% são do tipo borderline e aproximadamente 15% desses tumores recorrem após excisão cirúrgica. O tratamento recomendado para todos os tipos de tumor filoide é a excisão cirúrgica, e no caso de tumores gigantes o tratamento deve ser multidisciplinar. Apresentamos o caso de uma mulher de 46 anos com tumor filoide na mama esquerda que recorreu 4 anos após a excisão cirúrgica. O estudo anatomopatológico qualificou-o como tumor gigante e o estudo histopatológico relatou tumor filoide borderline. Foi submetida a excisão cirúrgica com mastectomia esquerda e reconstrução mamária com retalho de grande dorsal mais enxerto de gordura. A paciente apresentou evolução favorável sem recidiva. Concluindo, o tumor filoide gigante borderline recorrente é raro e seu manejo cirúrgico representa um desafio tanto na excisão quanto na reconstrução mamária.

Phyllodes tumor is a rare fibroepithelial neoplasm that represents 0.3 to 1% of all breast neoplasms. According to histopathologic classification, 12 to 26% are borderline type and approximately 15% of these tumors recur after surgical excision. The recommended treatment for all types of phyllodes tumor is surgical excision, and in the case of giant tumors the treatment should be multidisciplinary. We present the case of a 46-yearold woman with a phyllodes tumor in the left breast that recurred 4 years after surgical excision. The anatomopathological study qualified it as a giant tumor and the histopathological study reported a borderline phyllodes tumor. She underwent surgical excision with left mastectomy and breast reconstruction by means of a latissimus dorsi flap plus fat graft. The patient presented a favorable evolution without recurrence. In conclusion, the recurrent giant borderline phyllodes tumor is rare and its surgical management represents a challenge both in breast excision and reconstruction.

Associação do retalho miocutâneo do músculo peitoral maior e da mamaplastia em T invertido para reconstrução de extenso defeito da parede torácica: relato de caso / Association of pectoralis major myocutaneous flap and inverted T mammoplasty for reconstruction of extensive chest wall defect: case report

Introdução: Em 1977, a partir dos estudos anatômicos de McCraw et al., passou-se a utilizar o músculo peitoral maior como retalho miocutâneo em ilha. O presente artigo descreve um caso de reconstrução de um defeito da parede anterior do hemitórax direito através do retalho miocutâneo peitoral maior em ilha ipsilateral. Relato do Caso: A.E.S., de 66 anos, sexo masculino foi submetido a ressecção ampla de um carcinoma basocelular infiltrativo recidivante de 13,0 x 8,0cm da região paraesternal direita. O retalho miocutâneo foi transposto através de tunelização subcutânea e as cicatrizes posicionadas em forma de mamaplastia em T invertido. Conclusão: A presente tática cirúrgica é de fácil execução para cirurgiões habituados com reconstrução mamária, apresenta tempo cirúrgico curto e resultado estético-funcional satisfatório.

Introduction: In 1977, based on anatomical studies by McCraw et al., the pectoralis major muscle began to be used as an island myocutaneous flap. The present article describes a case of reconstruction of a defect in the anterior wall of the right hemithorax using the pectoralis major myocutaneous flap in an ipsilateral island. Case Report: AES, 66 years old, male, underwent wide resection of a recurrent infiltrative basal cell carcinoma measuring 13.0 x 8.0 cm in the right parasternal region. The myocutaneous flap was transposed through subcutaneous tunneling and the scars were positioned in the shape of an inverted T mammoplasty. Conclusion: This surgical tactic is easy to perform for surgeons accustomed to breast reconstruction, has a short surgical time, and has satisfactory aesthetic-functional results.

Tricoblastoma con estudio inmunohistoquímico: reporte de caso / Trichoblastoma with immunohistochemical study: case report

Resumen Introducción: El tricoblastoma es una neoplasia que por su baja frecuencia no se sospecha clínicamente, pero que debe ser diferenciada de un carcinoma de células basales a través del estudio histopatológico. Objetivo: Reportar un tumor sumamente raro que se presenta en sitios donde es frecuente observar carcinomas basocelulares. Caso clínico: Se presenta el caso de una paciente de 34 años, quien mostraba un nódulo deconsistencia firme y bordes definidos en la región frontal derecha. En laevaluación histológica, se encontró un nódulo hipodérmico bien circunscrito,constituidopormasasynidosdecélulasbasaloidesgrandesconnúcleoovoideo y nucléolo visible con empalizada periférica y algunos folículos rudimentarios. Ante estos signos histopatológicos, se planteó el diagnóstico diferencial con carcinoma de células basales y tricogerminoma,yaqueestasneoplasiaspresentanelementos comunes. La inmunohistoquímica mostró que las células tumorales eran positivas en mayor o menor porcentaje parap63,p53,CK20,Bcl2yCD10. Conclusiones: Pensar en el diagnóstico de un tricoblastoma es un reto, ya que tiene características similares al carcinoma de células basales y a otros tumores benignos foliculares como el tricogerminoma. Por ello, es necesario interrelacionar los hallazgos histomorfológicos con los resultados inmunohistoquímicos.

Abstract Introduction : Trichoblastoma is a neoplasm that is not clinically suspected due to its low frequency but must be differentiated from basal cell carcinoma through histopathological study. Aim : To report an extremely rare tumor that occurs in places where it is common to see basal cell carcinomas. Clinical case : The case of a 34-year-old patient is presented, who showed a nodule of firm consistency and defined edges on the right side of the forehead. In the histological evaluation a well-circumscribed hypodermal nodule was found consisting of masses and nests of large basaloid cells with an ovoid nucleus and visible nucleolus with peripheral palisade and some rudimentary follicles. Given these findings, the differential diagnosis with basal cell carcinoma and trichogerminoma was raised, since these neoplasms have common elements. Immunohistochemistry showed that tumor cells were positive in a higher or lesser percentage for: p63, p53, CK20, Bcl2 and CD10. Conclusions : Diagnosingatrichoblastoma is a challenge since it has characteristics similar to basal cell carcinoma and other benign follicular tumors such as trichogerminoma, so it is necessary to interrelate the histomorphological findings with the immunohistochemical results.

A clinicopathological analysis of cervical carcinoma with basaloid features / 实用医学杂志

Objective To investigate the clinical and pathological features of adenoid basal cell carcinoma(ABC),adenoid cystic carcinoma(ACC),and basaloid squamous cell carcinoma(BSCC)with basaloid charac-teristics and improve the diagnostic and differential diagnostic ability of clinicians and pathologists for these lesions.Methods A retrospective study was conducted on the clinical and pathological data of 4 cases of ABC,1 case of ACC,and 3 cases of BSCC diagnosed and treated at Shenzhen Maternal and Child Health Hospital,Southern Medical University from April 2018 to December 2022.Pathological slides were reviewed and relevant literature was analyzed and summarized.Results All three types of tumors were common in postmenopausal women and were associated with high-risk HPV infection.ABC was a low-grade cancer and patients were often clinically asymp-tomatic.It was usually detected incidentally during cervical screening due to cytological abnormalities,or after cervical cone biopsy or hysterectomy for HSIL.It presented as superficial cervical infiltration and clinical staging was often early.ACC and BSCC were intermediate to high-grade cancers and they often presented with postmenopausal vaginal bleeding.A visible mass was observed on the cervix.The clinical staging was intermediate to advanced.The three types of lesions could coexist.Careful observation of the morphological characteristics and immunohistochemical staining could help with differential diagnosis.None of the 8 patients experienced recurrence or metastasis during follow-up.Conclusion Cervical ABC,ACC and BSCC are rare and they originate from reserve cells.They share the similarities in clinical and pathological morphology,but differ in treatment and prognosis.So,accurate differen-tiation among them has important clinical significance.

Unilateral parotid gland Simultaneously primary two different pathological tumors: a case report and literature review / 口腔疾病防治

Objective@#To explore the clinical manifestations, histopathological characteristics, diagnosis, treatment, and prognosis of simultaneous unilateral primary tumors of different pathological types in the parotid gland.@*Methods@#A case of simultaneous unilateral primary parotid gland tumors, i.e., adenolymphoma and basal cell adenoma, was reviewed and analyzed in combination with the literature.@*Results@#The patient discovered a lump in the right parotid gland area one month prior to presentation, and a tumor was palpated in the shallow lobe of the right parotid gland before surgery. According to MR images, the initial diagnoses were tumors of the shallow and deep lobes of the right parotid gland. The tumors of the deep and shallow lobes were excised with part of the gland, and the facial nerves were dissected under general anesthesia. Postoperative pathology revealed an adenolymphoma in the shallow lobe of the right parotid gland and a basal cell adenoma with cystic transformation in the deep lobe. The surgical effect was good, with no complications, and there was no recurrence after 1 year of follow-up. A review of the relevant literature showed that multiple primary tumors of the parotid gland can manifest as the simultaneous presence of two or more types of tumors on both sides or on one side, and the disease is mainly treated with surgery.@*Conclusion@#Multiple unilateral primary parotid gland tumors are rare. Imaging examinations need to be combined with clinical evaluations to prevent missed diagnoses. Surgery is the first treatment option, and patients with benign tumors have a good prognosis.

Frequency of skin diseases in renal transplant recipients and patients with chronic kidney disease in a tertiary center: a cross-sectional study

ABSTRACT BACKGROUND: The prevalence of chronic kidney disease (CKD) has increased in the recent decades, along with the number of patients in the terminal stages of this disease, requiring transplantation. Some skin disorders are more frequent in patients with CKD and in renal transplant recipients (RTR). OBJECTIVES: To evaluate the frequency of skin diseases in RTR and patients with CKD receiving conservative treatment. DESIGN AND SETTING: This observational cross-sectional study recruited consecutive patients with CKD and RTR from a nephrology clinic at a teaching hospital in Brazil between 2015 and 2020. METHODS: Quantitative, descriptive, and analytical approaches were used. The sample was selected based on convenience sampling. Data were collected from dermatological visits and participants' medical records. RESULTS: Overall, 308 participants were included: 206 RTR (66.9%, median age: 48 years, interquartile range [IQR] 38.0-56.0, 63.6% men) and 102 patients with CKD (33.1%, median age: 61.0 years, IQR 50.0-71.2, 48% men). The frequency of infectious skin diseases (39.3% vs. 21.6% P = 0.002) were higher in RTR than in patients with CKD. Neoplastic skin lesions were present in nine (4.4%) RTR and in only one (1.0%) patient with CKD. Among the RTR, the ratio of basal cell carcinoma to squamous cell carcinoma was 2:1. CONCLUSIONS: This study revealed that an increased frequency of infectious skin diseases may be expected in patients who have undergone kidney transplantation. Among skin cancers, BCC is more frequently observed in RTR, especially in those using azathioprine.

Empleo de fotomarcación con ácido 5-aminolevulínico para la comparación de la extensión tumoral de carcinomas cutáneos clínicamente, dermatoscópicamente y por fotomarcación corroborado con la cirugía micrográfica de Mohs / Use of photomarking with 5-aminolevulinic acid for the comparison of tumor extension of skin carcinomas clinically, dermatoscopically, and by photomarking corroborated with Mohs micrographic surgery / Uso de fotomarcação com ácido 5-aminolevulínico para a comparação da extensão tumoral de carcinomas cutâneos clinicamente, dermatoscopicamente e por fotomarcação corroborada com a cirurgia micrográfica de Mohs

Introducción: La fotomarcación es una técnica no invasiva que consiste en la aplicación de un fotosensibilizador y la posterior visualización con lampara de Wood para determinar los márgenes de cáncer de piel no melanoma. Esto podría ser de utilidad en conjunto con la cirugía micrográfica de Mohs, al definir de manera más precisa los márgenes histológicos tumorales. Objetivo: Comparar los límites tumorales entre la demarcación clínica, la dermatoscópica y la demarcación con ALA en carcinomas cutáneos, y corroborarlos con el defecto quirúrgico obtenido por la CMM. Método: Estudio observacional, descriptivo y prospectivo. Se compararon las áreas tumorales de cáncer de piel no melanoma observadas por clínica, dermatoscopía, fotomarcación y defecto quirúrgico final. Resultados: El promedio del área clínica fue 1,77 cm2 (DE 0,55), el promedio de área dermatoscópica fue 1,93 cm2 (DE 0,55), el promedio del área por fotomarcación fue 2,14 cm2 (DE 0,55) y el promedio del área del defecto quirúrgico final fue 4,41 cm2 (DE 1,12). Conclusiones: No se logró comprobar que la fotomarcación tenga una ventaja estadísticamente significativa respecto a la marcación clínica y dermatoscópica. Se requieren más estudios para determinar el rol de esta técnica.

Introduction: Photomarking is a non-invasive technique that involves the application of a photosensitizer and subsequent visualization with a Wood's lamp to determine the margins of non-melanoma skin cancer. This could be useful in conjunction with Mohs micrographic surgery by more precisely defining the histological tumor margins. Objective: To compare the tumor limits between clinical demarcation, dermatoscopic demarcation, and ALA demarcation in cutaneous carcinomas, and corroborate them with the surgical defect obtained by MMS. Method: Observational, descriptive, and prospective study. The tumor areas of non-melanoma skin cancer observed by clinic, dermatoscopy, photomarking, and final surgical defect were compared. Results: The average clinical area was 1,77 cm2 (SD 0.55), the average dermatoscopic area was 1,93 cm2 (SD 0,55), the average area by photomarking was 2,14 cm2 (SD 0,55), and the average area of the final surgical defect was 4,41 cm2 (SD 1,12). Conclusions: It was not possible to demonstrate that photomapping provides a statistically significant advantage over clinical and dermatoscopic marking. Further studies are needed to determine the role of this technique.

Introdução: A fotomarcação é uma técnica não invasiva que envolve a aplicação de um fotossensibilizador e a subsequente visualização com lâmpada de Wood para determinar as margens do câncer de pele não melanoma. Isso poderia ser útil em conjunto com a cirurgia micrográfica de Mohs ao definir de forma mais precisa as margens histológicas tumorais. Objetivo: Comparar os limites tumorais entre a demarcação clínica, a demarcação dermatoscópica e a demarcação com ALA em carcinomas cutâneos, e corroborá-los com o defeito cirúrgico obtido pela CMM. Método: Estudo observacional, descritivo e prospectivo. Foram comparadas as áreas tumorais de câncer de pele não melanoma observadas por clínica, dermatoscopia, fotomarcação e defeito cirúrgico final. Resultados: A média da área clínica foi de 1,77 cm2 (DP 0,55), a média da área dermatoscópica foi de 1,93 cm2 (DP 0,55), a média da área por fotomarcação foi de 2,14 cm2 (DP 0,55) e a média da área do defeito cirúrgico final foi de 4,41 cm2 (DP 1,12). Conclusões: Não foi possível comprovar que a fotomarcação tenha uma vantagem estatisticamente significativa em relação à marcação clínica e dermatoscópica. Mais estudos são necessários para determinar o papel dessa técnica.

Primary basal cell carcinoma of the caruncle: case report and review of the literature

ABSTRACT We present a rare case of primary caruncle basal cell carcinoma (BCC), a condition with limited occurrences. Our patient, an 80-year-old woman without prior ocular pathological history, presented a 2x2mm pedunculated blackish nodular lesion on the caruncle of her left eye, without local conjunctival or cutaneous involvement. Histological analysis following complete excision confirmed the presence of basal cell carcinoma within the caruncle. Over a span of 30 months, no recurrence has been observed. While scant cases are documented in the literature, we conducted a review of these instances. Despite its infrequent manifestation, this condition should be taken into account when evaluating caruncular tumors, given its tendency to invade the orbit. Complete excision with free surgical margins is the treatment of choice, and adjuvant radiotherapy or chemotherapy might be considered.

Respuesta terapéutica del HeberFERON® en pacientes con carcinoma basocelular y su asociación con la COVID-19

Introducción: El carcinoma basocelular constituye uno de los tipos de cáncer cutáneo de mayor incidencia. El uso del HeberFERON® ha demostrado una efectiva respuesta clínica. Objetivo: Evaluar la respuesta del HeberFERON® en pacientes con carcinoma basocelular asociado a la COVID-19, y su comportamiento en pacientes con igual diagnóstico dermatológico sin tratamiento previo con dicho fármaco, atendidos con cirugía. Materiales y métodos: Se realizó un estudio observacional descriptivo y retrospectivo en un universo de 184 pacientes adultos con carcinoma basocelular. Se analizaron las variables edad, sexo, fototipo de piel, comorbilidades asociadas, infección con SARS-CoV-2 asociada con tratamiento previo con HeberFERON® o cirugía; tiempo entre tratamiento recibido y padecimiento de COVID-19, y severidad de los síntomas. Los resultados se expresan en tablas. Resultados: Se estudiaron 94 pacientes tratados con HeberFERON® para el carcinoma basocelular, y 90 pacientes tratados con cirugía. Predominaron los masculinos, mayores de 60 años, fototipo de piel II-III, con comorbilidades cardiovasculares. De ellos, 24 (25,5 %) resultaron positivos a la COVID-19, y el 83,3 % desarrollaron síntomas leves. De los tratados con cirugía para el carcinoma basocelular, 61 resultaron positivos a la COVID-19 (67,7 %), y el 55,7 % tuvo sintomatología severa. Durante el ciclo de tratamiento con HeberFERON para el carcinoma basocelular, el 66,7 % enfermó con COVID-19 entre las 16 y 32 semanas. Posterior a las 32 semanas, se reportó un fallecido. Conclusiones: Los pacientes tratados con cirugía sin previo HeberFERON tuvieron más contagios con COVID-19, predominando los decesos asociados a ello, siendo menor en los que lo recibieron. De los tratados previamente con HeberFERON® para el carcinoma basocelular, el 74,5 % no enfermó de COVID-19, a pesar de haber sido el 52,8 % contactos de positivos al SARS-CoV-2.

Introduction: Basal cell carcinoma is one of the types of skin cancer with the highest incidence. The use of HeberFERON® has shown an effective clinical response. Objective: To evaluate the response of HeberFERON® in patients with BCC associated with COVID-19 and its behavior in patients with the same dermatological diagnosis without previous treatment with that drug, treated with surgery. Materials and methods: A descriptive and retrospective observational study was conducted in a universe of 184 adult patients with basal cell carcinoma. The variables analyzed were age, sex, skin phototype, associated comorbidities, SARS-CoV-2 infection, associated to previously treatment with HeberFERON® or surgery; time between treatment received and suffering from COVID-19; severity of symptoms. The results were expressed in tables. Results: 94 patients were treated with HeberFERON® for basal cell carcinoma, and 90 were treated with surgery. There was a predominance of male patients, aged over 60 years, skin phototype II-III, with cardiovascular morbidities. Of them, 24 (25.5%) were positive to COVID-19 (67.7%), and 83.3% developed mild symptoms. Of those treated with surgery for basal cell carcinoma, 61 were positive to COVID-19 (67,7%), and 55.7% had severe symptoms. During the HeberFERON® treatment cycle for basal cell carcinoma, 66.7% became ill with COVID-19 between 16 and 32 weeks. After 32 weeks one deceased was reported. Conclusions: Patients treated with surgery without prior HeberFERON® had more infections with Covid-19, the deaths associated with it predominating, being less in those who received it. Of those previously treated with HeberFERON® for basal cell carcinoma, 74.5% did not become ill with COVID-19, despite having been 52.8% contacts to SARS-CoV-2 positive people.

Long-term follow-up of patients with high-risk facial basal cell carcinoma treated with interferon

Abstract Background Surgery is the treatment of choice for patients with basal cell carcinoma (BCC). When surgery is not a choice, only radiotherapy is recommended for patients with high-risk facial BCC. Interferon could be an acceptable therapeutic option for these patients. Objective To evaluate the long-term clinical response to interferon therapy in patients with high-risk facial BCC. Methods Patients with high-risk facial BCC were treated with perilesional injections of alpha-2b+ gamma interferons. Those with incomplete clinical response were reevaluated, their residual tumors excised, and declared cured. Patients treated with interferon and those treated with interferon plus surgery were followed for five years. Time to recurrence and the emergence of a new facial BCC were estimated by Kaplan-Meier survival analysis. Adverse events were documented. Results This study included 195 participants; 143 (73.3%) showed a complete response (95% CI 67.2‒80.1). Patients developed recurrence after a mean of 55 months (95% CI 53.8‒57.4). The estimated rate of recurrence was 12.3% (95% CI 7.4‒17.1). Patients developed a new BCC after a mean of 52.7 months (95% CI 50.4‒54.9). The estimated rate for development of a new BCC was 20.0% (95% CI 14.4‒25.9). Fifteen (7.7%) patients abandoned the study during follow-up. Adverse events were frequent but moderate or mild; fever and local pain were the most frequent. Study limitations Observational cohort design without a control group for comparison. Conclusions Perilesional injections of alpha-2b+ gamma interferons in patients with facial high-risk BCC offer a satisfactory cure rate after five years of follow-up with an acceptable safety profile.

Carcinoma basocelular de la piel cabelluda tratado con HeberFERON. Seguimiento clínico, ecográfico e histopatológico

Fundamento: El carcinoma basocelular es infrecuente en la piel cabelluda. Es un tumor de invasión local y crecimiento lento, puede ser agresivo, destruir tejidos vecinos, causar ulceración e invadir en profundidad cartílago y hueso. Objetivo: Evaluar los resultados de la aplicación del HeberFERON y el seguimiento con ecografía cutánea en pacientes con carcinoma basocelular en la piel cabelluda. Metodología: Se realizó un estudio observacional, descriptivo y longitudinal en una serie de casos con diagnóstico de carcinoma basocelular de la piel cabelluda en el Policlínico Centro de la ciudad Sancti Spíritus, durante el período de 10 de julio del 2018 a 29 de julio del 2022. Se incluyeron 6 casos. Las variables estudiadas fueron la respuesta al tratamiento mediante la clínica, la ecografía cutánea e histopatología y presencia de eventos adversos. Resultados: Predominó el sexo masculino, subtipo histológico sólido, subtipo clínico nódulo ulcerativo, tamaño del tumor mayor de 30 mm y tiempo de evolución de más de 12 meses; la respuesta al tratamiento en la mayoría de los casos fue parcial. Los eventos adversos fueron dolor y ardor en el sitio de inyección, fiebre, edema y eritema perilesional. Conclusiones: El HeberFERON resultó de utilidad en los pacientes con carcinoma basocelular del cuero cabelludo ya que redujo el tumor en unos casos y en otros lo eliminó. La ecografía permitió la evaluación en tiempo real de la neoplasia; los eventos adversos más frecuentes fueron la fiebre y el dolor en el sitio de inyección, a pesar de ello ningún paciente abandonó el tratamiento.

Background: Basal cell carcinoma is uncommon in the scalp. It is a slow-growing locally invasive tumor, it can be aggressive in destroying neighboring tissues, cause ulceration and invade deep into the cartilage and bone. Objective: To evaluate the results of HeberFERON application and follow-up with cutaneous echographical in patients with scalp basal cell carcinoma. Methodology: An observational, descriptive and longitudinal study was conducted in a series of cases diagnosed with scalp basal cell carcinoma at the Center Polyclinic in Sancti Spíritus city during the period from July 10, 2018 to July 29, 2022. Six clinical cases were included. The studied variables were the answer to the treatment by clinical, cutaneous echographical and histopathology and the presence of adverse events. Results: Male sex predominated, solid histologic subtype, clinical subtype ulcerative nodule, tumor size greater than 30 mm and evolution time of over 12 months; the treatment response in most cases was partial; adverse events were pain and burning at the injection site, fever, edema and perilesional erythema. Conclusion: It was observed that in patients with scalp basal cell carcinoma, the HeberFERON treatment reduced in some cases and eliminated the tumor in others. Echography allowed real-time evaluation of the neoplasm, fever and pain at the injection site were the most frequent adverse events. In spite of this, none of the patients abandoned the therapy.

Antecedente de grado de expresividad de p53 en carcinomas basocelulares como predictor de recurrencia / Background of p53 expressivity grade in basal cell carcinomas as a predictor of recurrence

INTRODUCCIÓN. El gen Tp53 proporciona instrucciones para producir proteína tumoral 53. El Tp53 es un gen supresor tumoral que protege el ciclo celular, reparando el ADN o activando la apoptosis. Es clave en la carcinogénesis del carcinoma basocelular, patología que cobra relevancia en Ecuador, debido a su latitud y altitud, factores que determinan un mayor daño por exposición a radiación ultravioleta y por ende para carcinoma basocelular. Estudios sugieren que la inmunoexpresión de la proteína tumoral 53 podría ser un predictor de recurrencia en esta neoplasia. OBJETIVO. Determinar si el grado de expresividad de especies mutadas de proteína tumoral 53 en pacientes con carcinoma basocelular es una variable que tiene relación con la recurrencia y agresividad en los diferentes subtipos histológicos. MATERIALES Y MÉTODOS. Estudio de revisión bibliográfica de diferentes artículos científicos publicados en revistas indexadas y bases de datos durante los últimos diez años: ElSevier, Medigraphic, PubMed, Redalyc, ResearchGate, ScienceDirect, SpringerLink, Cochrane Database of Systematic Reviews. RESULTADOS. Se obtuvieron 104 resultados de los cuales se seleccionaron 50 artículos científicos que incluyeron revisiones sistemáticas, meta-análisis, artículos originales y reportes de casos en idiomas español e inglés. CONCLUSIÓN. Tp53 se encuentra mutado en más del 50% de carcinomas basocelulares y tiene un rol clave en su carcinogénesis. La inmunoexpresión aberrante de proteína tumoral 53 es un marcador de riesgo de recurrencia y agresividad en carcinoma basocelular, como lo indican los artículos revisados. Sin embargo, se requiere estudios locales que establezcan el verdadero valor de proteína tumoral 53 como marcador de recurrencia y/o agresividad en la población ecuatoriana.

INTRODUCTION. The Tp53 gene provides instructions to produce tumor protein 53. Tp53 is a tumor suppressor gene that protects the cell cycle, repairing DNA or activating apoptosis. It is key in the carcinogenesis of basal cell carcinoma, a pathology that is relevant in Ecuador, due to its latitude and altitude, factors that determine greater damage by exposure to ultraviolet radiation and therefore for basal cell carcinoma. Studies suggest that the immunoexpression of tumor protein 53 could be a predictor of recurrence in this neoplasm. OBJECTIVE. To determine whether the degree of expression of mutated species of tumor protein 53 in patients with basal cell carcinoma is a variable related to recurrence and aggressiveness in the different histologic subtypes. MATERIALS AND METHODS. Bibliographic review study of different scientific articles published in indexed journals and databases during the last ten years: El-Sevier, Medigraphic, PubMed, Redalyc, ResearchGate, ScienceDirect, SpringerLink, Cochrane Database of Systematic Reviews. RESULTS. A total of 104 results were obtained from which 50 scientific articles were selected, including systematic reviews, meta-analyses, original articles and case reports in Spanish and English. CONCLUSIONS. Tp53 is mutated in more than 50% of basal cell carcinomas and plays a key role in their carcinogenesis. Aberrant immunoexpression of tumor protein 53 is a risk marker for recurrence and aggressiveness in basal cell carcinoma, as indicated by the reviewed articles. However, local studies are required to establish the true value of tumor protein 53 as a marker of recurrence and/or aggressiveness in the Ecuadorian population.

Resultados del uso de HeberFERON® en pacientes con carcinoma basocelular de alto riesgo en Matanzas

Introducción: El cáncer de piel es la más frecuente de todas las neoplasias. Su incidencia mundial ha aumentado en proporción epidémica, y existe un predominio en países tropicales debido a la constante exposición solar. El carcinoma basocelular es el que más afecta a la población y predomina en hombres de más de 60 años. Existen criterios para clasificar esta entidad en alto riesgo, basándose, sobre todo, en la localización y extensión de la lesión. Una opción novedosa y terapéutica de elección es el uso del HeberFERON®. Objetivo: Describir la respuesta clínica al tratamiento con HeberFERON® en pacientes con carcinoma basocelular de alto riego en Matanzas, en el período de febrero de 2019 a julio de 2021. Materiales y métodos: Se realizó un estudio descriptivo prospectivo en pacientes atendidos en la Consulta Provincial de Tumores Periféricos, de Matanzas, que presentaron carcinoma basocelular de alto riesgo en el período mencionado. Resultado: La población estuvo constituida por 55 pacientes, predominando los hombres y el grupo etario de 60 a 69 años. Las variantes ulceradas localizadas en la nariz constituyeron las formas clínicas agresivas de mayor incidencia. Conclusiones: Imperaron las respuestas completas en tumores mayores de 2 cm, evitando cirugías mutilantes, con lo que se evidencia la seguridad y eficacia del HeberFERON®.

Introduction: Skin cancer is the most frequent of all neoplasms. Its worldwide incidence has increased in epidemic proportions, and there is predominance in tropical countries due to constant sun exposition. Basal cell carcinoma is the one that most affects the population and predominates in men over 60 years of age. There are criteria to classify this entity as high risk, based, above all, in the location and extent of the lesion. A novel and therapeutic option of election is the use of HeberFERON™. Objective: To describe the clinical response to treatment with HeberFERON™ in patients with high-risk basal cell carcinoma in Matanzas, from February 2019 to July 2021. Materials and methods: Prospective, descriptive study was carried out in patients treated at the Provincial Clinic of Peripheral Tumors, of Matanzas, who presented high-risk basal cell carcinoma in the aforementioned period. Results: The population consisted of 55 patients, predominating men and the age group from 60 to 69 years. The ulcerative forms located in the nose constituted the aggressive clinical forms of highest incidence. Conclusions: Complete responses prevailed in tumors larger than 2 cm, avoiding mutilating surgeries, thus demonstrating the safety and efficacy of HeberFERON™.

HeberFERON en el tratamiento de pacientes con carcinoma basocelular en zona de alto riesgo / HeberFERON in the Treatment of Patients with Basal Cell Carcinoma on a High-Risk Zone

Introducción: El carcinoma basocelular es un tumor de invasión local de crecimiento; se origina en las células epidérmicas de los folículos pilosos o las células basales de la epidermis, cuando se localizan en zona de alto riesgo en la cara tienen un mayor índice de recurrencia tumoral y de invasión a estructuras adyacentes y subyacentes. Objetivo: Evaluar los resultados de la aplicación del HeberFERON en pacientes con carcinoma basocelular en zona de alto riesgo. Métodos: Se realizó un estudio observacional, descriptivo y prospectivo en pacientes con diagnóstico clínico, dermatoscópico e histopatológico de carcinoma basocelular en zona de alto riesgo, tratados con HeberFERON en la consulta del Policlínico Centro de Sancti Spíritus desde el 12 de enero de 2016 hasta el 25 de marzo de 2022. La muestra quedó conformada por 62 pacientes Las principales variables estudiadas fueron la respuesta al tratamiento y los eventos adversos. Resultados: Predominó el sexo masculino, el área urbana, fototipocutáneo III y la edad mayor de 40 años. La localización más frecuente fue la nasal; el subtipo clínico el nódulo ulcerativo; el histológico, el sólido; el tumor primitivo y menor de 2 cm; la respuesta al tratamiento fue completa en la mayoría de los pacientes. Los eventos adversos más comunes fueron dolor y ardor en el sitio de inyección, edema y eritema perilesional, fiebre y cefalea. Conclusiones: La mayoría de los pacientes tratados con HeberFERON tuvieron una respuesta completa, los eventos adversos fueron los descritos en la literatura por el uso de interferones, sin cambio en la actitud farmacológica(AU)

Introduction: Basal cell carcinoma is a growing and locally invasive tumor; it originates in the epidermal cells of hair follicles or the basal cells of the epidermis. When located in a high-risk facial zone, they present a higher rate of tumor recurrence and invasion to adjacent and underlying structures. Objective: To evaluate the results of HeberFERON application in patients with basal cell carcinoma on a high-risk zone. Methods: An observational, descriptive and prospective study was conducted in patients with a clinical, dermatoscopic and histopathological diagnosis of basal cell carcinoma on a high-risk zone, treated with HeberFERON in the consultation of Policlínico Centro of Sancti Spíritus, from January 12, 2016 to March 25, 2022. The sample was made up of 62 patients. The main variables studied were response to treatment and adverse events. Results: There was a predominance of the male sex, the urban area, skin phototype III and age over 40 years. The most frequent localization was nasal; the clinical subtype, ulcerative nodule; the histological subtype, solid. The response to treatment was complete in most patients. The most common adverse events were pain and burning at the injection site, perilesional erythema and edema, fever and headache. Conclusions: Most patients treated with HeberFERON had a complete response; the adverse events were those described in the literature due to the use of interferons, with no change in pharmacological behavior(AU)

HeberFERON en el tratamiento de pacientes con carcinoma basocelular de la oreja / HeberFERON in the treatment of patients with basal cell carcinoma of the ear

Fundamento: El carcinoma basocelular de la región auricular es considerado uno de los más agresivos y con peor pronóstico, suele ser destructivo y mutilante por lo que el tratamiento conservador, como es el uso de los interferones, es importante en la práctica médica habitual. Objetivo: Evaluar los resultados de la aplicación del HeberFERON en una serie de pacientes con carcinoma basocelular en la región auricular. Metodología: Se realizó un estudio observacional, descriptivo y longitudinal en una serie de casos con diagnóstico clínico, dermatoscópico e histopatológico de carcinoma basocelular de la oreja que recibieron tratamiento con HeberFERON en el Policlínico Centro de la ciudad Sancti Spíritus, durante el período del 20 de febrero de 2017 a 20 de diciembre de 2022. En total se incluyeron 29 pacientes. Se realizó una evaluación inicial, durante y 16 semanas después del tratamiento; se les inyectó 10.5 UI de HeberFERON 3 veces por semana perilesional e intradérmico hasta completar 9 dosis. Las variables fueron la respuesta al tratamiento y presencia o no de eventos adversos. Resultados: Predominó el sexo masculino, la localización en la concha de la oreja, subtipo clínico nódulo ulcerativo y el histológico sólido, con respuesta completa en la mayoría de los pacientes. Como eventos adversos más comunes se presentaron dolor en el sitio de inyección, fiebre, edema y eritema perilesional. Conclusiones: La respuesta al tratamiento fue favorable en la mayoría de los pacientes y los eventos adversos que se observaron fueron los descritos en la literatura sin cambio en la actitud farmacológica.

Background: Basal cell carcinoma of the auricular region is one of the most aggressive cancers and with the worst prognosis, is usually destructive and mutilating, therefore conservative treatment, such as the use of interferons, is important in routine medical practice. Objective: To evaluate the results of HeberFERON application in a series of patients with basal cell carcinoma in the auricular region. Methodology: An observational, descriptive and longitudinal study was conducted on a series of cases with clinical, dermoscopic and histopathologic diagnosis of basal cell carcinoma of the ear treated with HeberFERON at the Center Polyclinic in Sancti Spíritus city, during the period from February 20, 2017 through December 20, 2022. A total of 29 patients were included in the study. An evaluation was conducted at the start of treatment, during treatment, and 16 weeks after treatment; the patients were treated with 10.5 IU of HeberFERON by perilesional and intradermal injections three times a week until completing nine doses. The variables were the response to the treatment and the presence or absence of any adverse events. Results: The male sex predominated, location in the ear turbinate, clinical subtype ulcerative nodule and solid histologic subtype, with a complete response in the majority of patients. The most common adverse events were injection site pain, fever, edema, and perilesional erythema. Conclusions: The response to treatment was favorable in most patients, and the adverse events observed were those described in the literature, with no change in pharmacologic attitude.

Adequacy of surgical margins, re-excision, and evaluation of factors associated with recurrence: a retrospective study of 769 basal cell carcinomas

Abstract Background: Achieving adequate surgical margins and preventing recurrence are important in the treatment of basal cell carcinoma (BCC). Objectives: The objectives of this study were to evaluate the adequacy of surgical margins and the re-excision rates in patients with primary BCC who underwent standard surgical treatment using our proposed algorithm and to define the risk factors in patients with recurrent BCC. Methods: The medical records of patients who were histopathologically diagnosed with BCC were reviewed. An algorithm created based on previous literature was used to determine the distribution of optimal surgical margins adequacy and re-excision rates. Results: Statistically significant differences were observed between the cases with and without recurrence in age at diagnosis (p = 0.004), tumor size (p = 0.023), tumor location in the H zone of the face (p = 0.005), and aggressive histopathological subtype (p = 0.000). When the tumors were evaluated for adequacy of deep and lateral surgical margins and re-excision rates, higher rates of adequate excision (457 cases, 68.0%) and re-excision (43 cases, 33.9%) were noted for tumors in the H or M zone. Study limitations: Inadequate follow-up of newly diagnosed patients in terms of recurrence and metastasis and the retrospective application of our proposed algorithm are the limitations of the present study. Conclusions: Our results showed that if BCC was detected at an early age and at an early stage, recurrence was lower. The H and M zones were the regions with the highest rates of optimal surgical outcomes.